Compare ATEN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEN | BEAM |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2014 | 2019 |
| Metric | ATEN | BEAM |
|---|---|---|
| Price | $27.49 | $26.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $26.33 | ★ $50.75 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $235,429,000.00 | $24,000.00 |
| Revenue This Year | $13.02 | N/A |
| Revenue Next Year | $10.82 | $33.77 |
| P/E Ratio | $97.04 | ★ N/A |
| Revenue Growth | 2.36 | ★ 33.33 |
| 52 Week Low | $16.52 | $15.60 |
| 52 Week High | $38.49 | $38.26 |
| Indicator | ATEN | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 33.43 | 43.19 |
| Support Level | $16.92 | $25.88 |
| Resistance Level | $28.39 | $28.96 |
| Average True Range (ATR) | 1.52 | 1.36 |
| MACD | -0.52 | 0.25 |
| Stochastic Oscillator | 5.40 | 56.32 |
A10 Networks Inc is a provider of secure application and network infrastructure solutions for enterprises and service providers across on-premises, hybrid cloud, and distributed environments. The company's offerings include application delivery and traffic management, distributed denial-of-service (DDoS) protection, application and API security, and centralized management. It serves customers across multiple industries, including telecommunications, technology, financial services, public sector, industrial, retail, gaming, and education. The majority of the company's revenue is derived from the sale of secure networking and cybersecurity solutions and related maintenance and support services.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.